ATE413388T1 - Muskarin antagonisten - Google Patents
Muskarin antagonistenInfo
- Publication number
- ATE413388T1 ATE413388T1 AT03726436T AT03726436T ATE413388T1 AT E413388 T1 ATE413388 T1 AT E413388T1 AT 03726436 T AT03726436 T AT 03726436T AT 03726436 T AT03726436 T AT 03726436T AT E413388 T1 ATE413388 T1 AT E413388T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- formula
- compound
- muscarine antagonists
- methods
- Prior art date
Links
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37609302P | 2002-04-26 | 2002-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE413388T1 true ATE413388T1 (de) | 2008-11-15 |
Family
ID=29270760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03726436T ATE413388T1 (de) | 2002-04-26 | 2003-04-24 | Muskarin antagonisten |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6890936B2 (de) |
| EP (1) | EP1499596B1 (de) |
| JP (2) | JP4527408B2 (de) |
| CN (1) | CN1649845A (de) |
| AT (1) | ATE413388T1 (de) |
| AU (1) | AU2003228674A1 (de) |
| CA (1) | CA2484217A1 (de) |
| DE (1) | DE60324544D1 (de) |
| ES (1) | ES2315494T3 (de) |
| MX (1) | MXPA04010552A (de) |
| WO (1) | WO2003091220A1 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004233863B2 (en) | 2003-04-24 | 2010-06-17 | Incyte Holdings Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| CN101044134A (zh) * | 2004-09-20 | 2007-09-26 | 塔加西普特公司 | 具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物 |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2066355A2 (de) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese |
| US20080103105A1 (en) * | 2006-09-22 | 2008-05-01 | Braincells, Inc. | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS |
| US20080108574A1 (en) * | 2006-09-27 | 2008-05-08 | Braincells, Inc. | Melanocortin receptor mediated modulation of neurogenesis |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| EP2481408A3 (de) | 2007-03-01 | 2013-01-09 | Probiodrug AG | Neue Verwendung von Inhibitoren der Glutaminyl Cyclase |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| US20110212928A1 (en) | 2010-02-09 | 2011-09-01 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| WO2011143457A2 (en) | 2010-05-12 | 2011-11-17 | Northwestern University | Compositions and methods for treating or preventing atrial fibrillation |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2968220B1 (de) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| MX2017005484A (es) | 2014-10-31 | 2017-10-20 | Indivior Uk Ltd | Compuestos antagonistas del receptor de dopamina d3. |
| NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| ES3064093T3 (en) | 2017-10-20 | 2026-04-22 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| TWI767148B (zh) * | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04225953A (ja) * | 1990-05-07 | 1992-08-14 | Shionogi & Co Ltd | スピロ ジベンゾスベラン誘導体 |
| GB9309422D0 (en) * | 1993-05-07 | 1993-06-23 | Res Inst Medicine Chem | Chemical compounds |
| WO1999032489A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| US7164024B2 (en) * | 2001-04-20 | 2007-01-16 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
-
2003
- 2003-04-24 ES ES03726436T patent/ES2315494T3/es not_active Expired - Lifetime
- 2003-04-24 CN CNA038094436A patent/CN1649845A/zh active Pending
- 2003-04-24 JP JP2003587783A patent/JP4527408B2/ja not_active Expired - Fee Related
- 2003-04-24 CA CA002484217A patent/CA2484217A1/en not_active Abandoned
- 2003-04-24 MX MXPA04010552A patent/MXPA04010552A/es unknown
- 2003-04-24 EP EP03726436A patent/EP1499596B1/de not_active Expired - Lifetime
- 2003-04-24 WO PCT/US2003/012694 patent/WO2003091220A1/en not_active Ceased
- 2003-04-24 AU AU2003228674A patent/AU2003228674A1/en not_active Abandoned
- 2003-04-24 AT AT03726436T patent/ATE413388T1/de not_active IP Right Cessation
- 2003-04-24 DE DE60324544T patent/DE60324544D1/de not_active Expired - Lifetime
- 2003-04-28 US US10/425,376 patent/US6890936B2/en not_active Expired - Fee Related
-
2009
- 2009-12-16 JP JP2009285736A patent/JP2010059213A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP4527408B2 (ja) | 2010-08-18 |
| DE60324544D1 (de) | 2008-12-18 |
| EP1499596B1 (de) | 2008-11-05 |
| JP2010059213A (ja) | 2010-03-18 |
| AU2003228674A1 (en) | 2003-11-10 |
| US6890936B2 (en) | 2005-05-10 |
| MXPA04010552A (es) | 2005-01-25 |
| ES2315494T3 (es) | 2009-04-01 |
| HK1068136A1 (en) | 2005-04-22 |
| CN1649845A (zh) | 2005-08-03 |
| EP1499596A1 (de) | 2005-01-26 |
| JP2006507220A (ja) | 2006-03-02 |
| US20040067972A1 (en) | 2004-04-08 |
| CA2484217A1 (en) | 2003-11-06 |
| WO2003091220A1 (en) | 2003-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60324544D1 (de) | Muskarin antagonisten | |
| IL166271A0 (en) | Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same | |
| UA88012C2 (uk) | Похідні хіназоліндіону як інгібітори parp | |
| SE0101675D0 (sv) | Novel composition | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| ATE425149T1 (de) | ANILINOPYRIMIDIN DERIVATE ALS ßJNK PATHWAY INHIBITORENß, ZUSAMMENSETZUNGEN UND DAMIT VERBUNDENE BEHANDLUNGSMETHODEN | |
| BRPI0410630A (pt) | antagonista de nk1 | |
| DE60142921D1 (de) | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren | |
| IS6658A (is) | Ný efnasambönd | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| DK0842934T3 (da) | 5-HT1F agonister | |
| ATE250590T1 (de) | Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems | |
| UA93351C2 (uk) | Похідні фталазіну як інгібітори parp | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| DE60323942D1 (de) | Lipase-hemmende zusammensetzung | |
| ATE498600T1 (de) | Inden derivate als pharmazeutika | |
| ATE359283T1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
| SE0003476D0 (sv) | Compounds | |
| BR0212899A (pt) | Compostos orgânicos | |
| AP2001002188A0 (en) | 5HT1 antagonists for antidepressant therapy. | |
| ATE335739T1 (de) | Cak inhibitoren und deren verwendungen | |
| ID25478A (id) | Agonis 5-ht1f | |
| ATE394105T1 (de) | Substituierte 4,5-dihydro-1,2,4-triazin-3-one, 1, 2,4-triazin-3-one sowie deren verwendung als fungizide und insektizide | |
| GB0223223D0 (en) | Organic compounds | |
| NO20042138L (no) | Forbindelser og fremgangsmate for behandling av hyperaktiv blaere |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |